JohnDavidPurvianceMD

Radiation Oncology • Casper, WY

Physician

Join to view full profile

Dr. Purviance is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Purviance's full profile

Already have an account?

Office
6501 E 2nd St
Rocky Mountain Oncology Center
Casper, WY 82609
Phone+1 307-235-5433

Fax+1 307-233-4700

Education & Training

Tufts Medical CenterResidency, Radiation Oncology, 2003 - 2007
St Elizabeth's Medical Center/Lemuel Shattuck HospitalInternship, Transitional Year, 2002 - 2003
Tufts University School of MedicineClass of 2002

Certifications & Licensure

WY State Medical License 2007 - 2025
NV State Medical License 2022 - 2022
American Board of Radiology Radiation Oncology

Publications & Presentations

PubMed

95 citations
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Howard Safran, Thomas A. DiPetrillo, Paul A. Akerman, Thomas Ng, Devon Evans
International Journal of Radiation Oncology, Biology, Physics. 2007-02-01
44 citations
ASSEMBLY OF T-ANTIGEN DOUBLE HEXAMERS ON THE SIMIAN VIRUS 40 CORE ORIGIN REQUIRES ONLY A SUBSET OF THE AVAILABLE BINDING SITES
Woo S. Joo, Henry Y. Kim, John D. Purviance, Kodangattil Sreekumar, Peter A. Bullock
Molecular and Cellular Biology. 1998-05-01
1 citations
In the Simian Virus 40 In Vitro Replication System, Start Site Selection by the Polymerase α-Primase Complex Is Not Significantly Altered by Changes in the Concentrati...
John D. Purviance, Andrea E. Prack, Brett A. Barbaro, Peter A. Bullock
Journal of Virology. 2001-07-15